The first group (“molecular low-grade”) consisted of those 29 tumors with biallelic inactivation of the NF1 tumor suppressor gene only and one tumor with biallelic inactivation of NF1 plus an activating missense mutation in PTPN11, a phosphatase that regulates the MAP kinase signaling pathway. This evidence concerns the gene PTPN11 and neoplasm.